AZ resolves Faslodex patent litigation in the US

This announcement contains inside information

13 July 2016 07:00


ASTRAZENECA ENTERS INTO AGREEMENT TO RESOLVE FASLODEX PATENT LITIGATION IN THE US

AstraZeneca today announced that it has entered into an agreement with Sandoz, Inc. and affiliates ("Sandoz") to resolve Faslodex (fulvestrant) patent litigation in the US relating to Sandoz's generic fulvestrant product, for which it is seeking FDA approval.

The US Faslodex patents in question are due to expire in January 2021, with paediatric exclusivity continuing until July 2021. On 12 July 2016, the United States District Court for the District of New Jersey entered a consent judgment filed by AstraZeneca and Sandoz, which includes an injunction preventing Sandoz from launching a generic fulvestrant product until 25 March 2019, or earlier in some circumstances.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com 

CONTACTS

Media Enquiries  
Neil Burrows UK/Global +44 7824 350541
Vanessa Rhodes UK/Global +44 7880 400690
Karen Birmingham UK/Global +44 7818 524012
Rob Skelding UK/Global +44 7392 103298
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
UK
Thomas Kudsk Larsen +44 7818 524185
Nick Stone Respiratory and Autoimmunity +44 7717 618834
Henry Wheeler Oncology +44 7788 354619
Craig Marks Finance, Fixed Income, M&A +44 7881 615764
Christer Gruvris Infection and Neuroscience +44 7827 836825
US
Lindsey Trickett Cardiovascular and Metabolic Diseases +1 240 543 7970
Mitchell Chan Oncology +1 240 477 3771
Toll-free +1 866 381 7277

Adrian Kemp
Company Secretary
AstraZeneca PLC

-ENDS-

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe